Where does Gene Therapy Systems, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Gene Therapy Systems, Inc. ranks #46,994 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Gene Therapy Systems, Inc. hold?

Gene Therapy Systems, Inc. holds 5 US utility patents granted between 2017 and 2022, spanning 1 technology areas.

What is Gene Therapy Systems, Inc.'s Innovation Score?

Gene Therapy Systems, Inc. has an Innovation Score of 24.2 out of 100 (14th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Gene Therapy Systems, Inc.'s patent grant rate increasing or decreasing?

Gene Therapy Systems, Inc.'s recent grant velocity is +50% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Gene Therapy Systems, Inc.'s patents?

Gene Therapy Systems, Inc.'s patents average 18.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Gene Therapy Systems, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Gene Therapy Systems, Inc.

Q: What technology areas does Gene Therapy Systems, Inc. focus on?

Gene Therapy Systems, Inc.'s top technology area is A61L (Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles) with 5 patents, ranking #628 of 2,589 assignees active in that subclass. Grants appear in 1 CPC subclasses total.

USPTO PatentsView assignee record - 5 granted patents across 1 technology areas, recorded in grant years 2017–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61L (Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES;).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Gene ranks #46,994 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 1 technology areas.

#46,994
of 49,997 US assignees by volume: 14th percentile
by Innovation Score (24.2/100): 18.6
avg claims per patent: +50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R46994 · US Corporation #46,994 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 5 grants
BOTTOM-DECILE #46,994/49,997
PHOTO-FINISH Gedex Systems
CPC-NARROW A61L · 1 areas
INNOV-THIN 24.2/100
CLAIMS-RICH 18.6 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Gedex Systems Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Gene’s 24.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (26%) Velocity 3.3 pts (14%) Breadth 3.5 pts (14%) Claim depth 11.2 pts (46%)

Qualcomm Incorporated · highest

85
Gene Therapy Systems · this assignee

24
Bioamber · near

24
Granite Tactical… · near

24
Hanwha Advanced… · near

24
Structural Wrap · near

24
3D Lighting… · lowest

7

What this shows Gene's Innovation Score is 24.2/100 (14th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Gene?

Each dot is one of Gene’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Gene’s own 18.6 claims/patent is ABOVE the 11.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Gene vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Gene's grants concentrate

Gene Therapy Systems, Inc. is a focused PatentsView assignee: 1 CPC subclasses with 100% of grants classified under A61L (Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES;). By volume, Gene sits between Gedex Systems Inc. and General Dynamics Land Systems—Canada.

Gene's three-year grant acceleration

Gene Therapy Systems, Inc. shows 1 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Gedex Systems

5
Gelmart Industries

5
Gemex Systems

5
Genfleet Therapeu…

5
Genecraft

5
Genedesign

5
Genedia Biotech

5
General Dynamics…

5
Gene Therapy Syst… ◀

5

What this shows Gene holds 5 patents at rank #47,149, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Gene

By rank, the assignees closest to #47,149 in granted patent volume.

Leaders in A61L (Methods OR Apparatus FOR Sterilising Materials OR Objects…)

Other assignees with the most granted patents in Gene's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Gene, neither rank-band nor same-CPC leaders (those blocks stay above). In A61L (Methods OR Apparatus FOR Sterilising Materials OR Objects…), Gene ranks #628 of 2,589 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (24 here).

Granite Tactical Vehicles Inc. 24 Bioamber Inc. 24 Structural Wrap, LLC 24 Hanwha Advanced Materials Corporation 24

Gene's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

24 14th percentile higher than 14% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Gene Therapy Systems, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	20.0%
2018	1	20.0%
2020	1	20.0%
2021	1	20.0%
2022	1	20.0%

Which technologies does Gene Therapy Systems, Inc. patent most?

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 5

Top 1 of 1 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Gene Therapy Systems, Inc.'s patent record in context - here's where to go next.

Gene Therapy Systems, Inc.'s lead technology class is A61L (Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES;), 100% of its portfolio - see every assignee active in that class. Explore A61L
Ranked #46,994 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Gene Therapy Systems, Inc. against Gedex Systems Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 24.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.